Compounding Study Guide

📖 Core Concepts Compounding – preparation of a medication to meet an individual patient’s prescription when a commercial product is unsuitable. Traditional (Patient‑Specific) Compounding – made on‑demand for one patient; regulated mainly by state boards (U.S.) or provincial standards (Canada). Non‑Traditional (Bulk) Compounding – makes advance batches for future use; treated as small‑scale manufacturing and subject to federal oversight (FDA 503B, Health Canada manufacturing rules). Sterile vs. Non‑Sterile – Sterile compounding must occur in ISO‑Class 5 (or equivalent) environments with laminar flow cabinets; non‑sterile requires powder containment hoods when hazardous or cross‑contamination risk exists. Outsourcing Facility (U.S.) – FDA‑registered bulk compounding operation (503B) that can supply hospitals but cannot resale to third parties. Red‑Flag Factors – FDA warning signs that a compounding operation may be violating the law (e.g., “copy” compounding, using withdrawn drugs). --- 📌 Must Remember 503A = patient‑specific, state‑regulated, no FDA pre‑approval. 503B = bulk (outsourcing), FDA‑registered, must follow USP <797>/<795>, cannot compound “copy” of FDA‑approved drug unless a shortage is declared. Sterile compounding requires a laminar flow cabinet, validated SOPs, and environmental monitoring. Non‑sterile hazardous work requires a powder containment hood. Prohibited drugs – any on FDA’s “unsafe or ineffective” list cannot be compounded. Label must include: “Compounded,” facility name, lot/batch number, dosage form, strength, and expiration. Error‑prone step in manual IV compounding: syringe pull‑back verification; barcode/gravimetric checks greatly reduce errors. --- 🔄 Key Processes Traditional Sterile IV Preparation Verify prescription and patient identity. Scan barcodes of each ingredient. Perform gravimetric weight check (target ± 5 %). Assemble in ISO 5 laminar flow cabinet. Document each step in workflow software. Outsourcing Facility (503B) Workflow Receive bulk prescription order. Confirm ingredient USP/NF compliance. Conduct sterility and potency testing on each batch. Apply REMS controls if required. Label and ship directly to the prescribing facility. Risk Assessment for Compounding (Canada/ Australia) Identify patient‑specific needs (allergy, dosage, route). Classify risk (low, moderate, high). Match facility level (cleanroom, containment hood). If facility inadequate → refer to qualified site. --- 🔍 Key Comparisons Traditional vs. Non‑Traditional Traditional: one‑patient, on‑demand, state‑regulated (503A). Non‑Traditional: batch‑made, akin to manufacturing, FDA‑registered (503B). 503A vs. 503B 503A: patient‑specific, no FDA pre‑approval, limited to “no copy” rule. 503B: bulk, FDA oversight, must meet USP standards, can supply hospitals. Sterile vs. Non‑Sterile Compounding Sterile: laminar flow cabinet, ISO 5, sterility testing. Non‑Sterile: may use standard pharmacy area; hazardous powders need containment hood. U.S. vs. Australia vs. Canada Regulation U.S.: 503A/503B, FDA authority, PCAB accreditation optional. Australia: legal if for therapeutic use, requires laminar flow cabinet (sterile) or powder hood (non‑sterile). Canada: Health Canada defines compounding; bulk = manufacturing needing an Establishment Licence. --- ⚠️ Common Misunderstandings “All compounding needs FDA approval.” – Only bulk (503B) compounding is federally regulated; patient‑specific (503A) is state‑regulated. “Copying a commercial product is always allowed.” – Prohibited for traditional compounding; outsourcing facilities may only copy under a declared shortage. “Any pharmacy can sell compounded drugs to third parties.” – Federal law forbids resale by any entity other than the outsourcing facility. “Sterile compounding can be done on a normal counter.” – Must be performed in a certified ISO 5 environment with a laminar flow cabinet. --- 🧠 Mental Models / Intuition “Tailor‑Shop vs. Factory” – Think of traditional compounding as a tailor making a custom suit for one client; non‑traditional compounding is a small factory producing a batch of identical suits. “Red‑Flag Radar” – Any element that looks like mass‑production (advance preparation, copying a marketed drug, using bulk active ingredients) triggers a red‑flag check. “Layered Safety” – Each step (prescription verification → barcode → gravimetric check → software guidance) adds a layer that catches errors before the next layer is reached. --- 🚩 Exceptions & Edge Cases Bulk compounding of a drug withdrawn for safety → still prohibited even if no commercial product exists. Compounding with a bulk ingredient that lacks FDA approval – allowed only under a 503B facility if the ingredient is USP‑listed; otherwise a red flag. Veterinary compounding – follows the Animal Medicinal Drug Use Clarification Act; may use flavors not permitted in human meds. Short‑supply “copy” compounding – allowed for outsourcing facilities only when an FDA‑declared shortage exists and appropriate controls are in place. --- 📍 When to Use Which Use Traditional (503A) Compounding when: Prescription is for a single patient. No commercial product meets the specific need (allergy, dosage, route). Use Non‑Traditional (503B) Outsourcing Facility when: High‑volume batch needed (e.g., hospital IV bags). Product is a shortage‑related copy and facility meets FDA requirements. Choose Sterile Process for any injectable, ophthalmic, or invasive route. Choose Non‑Sterile Process for oral liquids, topical creams, or veterinary preparations (unless hazardous). --- 👀 Patterns to Recognize “Advance preparation + no prescription” → red flag for illegal bulk compounding. “Identical formulation to a marketed drug” → likely prohibited copy compounding. “High error rates reported in manual IV” → look for barcode/gravimetric verification steps in the question. “Label missing lot number or “compounded” statement → non‑compliant product. --- 🗂️ Exam Traps Distractor: “All compounding must be FDA‑approved.” – Correct answer: only bulk (503B) compounding is FDA‑regulated. Distractor: “Outsourcing facilities can sell compounded drugs to any pharmacy.” – Wrong; resale is prohibited. Distractor: “Sterile compounding can be performed in a regular pharmacy counter if the technician wears gloves.” – Incorrect; requires ISO 5 cabinet. Distractor: “Copying a commercial drug is permissible if the pharmacist changes the flavor.” – False; still a prohibited copy under 503A. Distractor: “Non‑sterile compounding never needs containment equipment.” – Misleading; hazardous powders require a containment hood.